ATC Group: J01X Other antibacterials

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01X in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01X Other antibacterials

Group J01X contents

Code Title
J01XA Glycopeptide antibacterials
J01XB Polymyxins
J01XC Steroid antibacterials
J01XD Imidazole derivatives
J01XE Nitrofuran derivatives
J01XX Other antibacterials

Active ingredients in J01X

Active Ingredient

Colistimethate is a cyclic polypeptide antibacterial active substance that is derived from Bacillus polymyxa var colistinus and belongs to the polymyxin group. Polymyxins work by damaging the cell membrane and the resulting physiological effects are lethal to the bacterium. Polymyxins are selective for Gram-negative bacteria that have a hydrophobic outer membrane.

Colistin is a cyclic polypeptide antibacterial agent belonging to the polymyxin group. Polymyxins work by damaging the cell membrane and the resulting physiological effects are lethal to the bacterium. Polymyxins are selective for aerobic Gram-negative bacteria that have a hydrophobic outer membrane.

Dalbavancin is a bactericidal lipoglycopeptide. Its mechanism of action in susceptible Gram-positive bacteria involves interruption of cell wall synthesis by binding to the terminal D-alanyl-D-alanine of the stem peptide in nascent cell wall peptidoglycan, preventing cross-linking (transpeptidation and transglycosylation) of disaccharide subunits resulting in bacterial cell death.

Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only. The mechanism of action involves binding to bacterial membranes of both growing and stationary phase cells causing depolarisation and leading to a rapid inhibition of protein, DNA, and RNA synthesis.

Fosfomycin exerts a bactericidal effect on proliferating pathogens by preventing the enzymatic synthesis of the bacterial cell wall. Fosfomycin inhibits the first stage of intracellular bacterial cell wall synthesis by blocking peptidoglycan synthesis.

Fusidic acid belongs to a unique group of antibiotics, the fusidanes, which act to inhibit bacterial protein synthesis by blocking the lengthening of factor G. Fusidic acid is active against staphylococcus epidermidis and methicillin resistant staphylococci.

Lefamulin is a pleuromutilin antibacterial agent. It inhibits bacterial protein synthesis by interacting with the A- and P- sites of the peptidyl transferase centre (PTC) in the central part of domain V of the 23S rRNA of the 50S ribosomal subunit, preventing correct positioning of the tRNA.

Linezolid is a synthetic, antibacterial agent that belongs to a new class of antimicrobials, the oxazolidinones. It has in vitro activity against aerobic Gram-positive bacteria and anaerobic micro-organisms. Linezolid selectively inhibits bacterial protein synthesis via a unique mechanism of action.

Methenamine is a urinary antibacterial agent with a wide antibacterial spectrum covering both gram-positive and gram-negative organisms. Urinary antibacterial activity can be shown within 30 minutes of administration.

Metronidazole is an anti-infectious drug belonging to the pharmacotherapeutic group of nitroimidazole derivatives, which have effect mainly on strict anaerobes. This effect is probably caused by interaction with DNS and different metabolites.

Nitrofurantoin is a broad spectrum antibacterial agent, active against the majority of urinary pathogens. It is bactericidal in renal tissue and throughout the urinary tract. The wide range of organisms sensitive to the bacterial activity include Escherichia coli, Enteroccus faecalis, Klebsiella species, Enterobacter species, Staphylococcus species: (e.g. S. aureus, S. saprophyticus, S. epidermidis).

Oritavancin is used for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

Ornidazole is indicated for the treatment of Bacterial vaginosis. It is effective against Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia (Giardia intestinalis), and also against certain anaerobic bacteria such as Bacteroides and Clostridium spp., Fusobacterium spp., and anaerobic cocci.

Polymixin B is bactericidal against a wide range of gram negative bacilli. It exerts a bactericidal effect by binding to acid phospholipids in the cell wall and membranes of the bacterium, thereby rendering ineffective the osmotic barrier normally provided by the cell membrane.

Spectinomycin is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. Spectinomycin is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae.

Tedizolid is an oxazolidinone prodrug. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid is primarily active against Gram-positive bacteria.

Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.

Tinidazole is active against both protozoa and obligate anaerobic bacteria. The activity against protozoa involves Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia. The mode of action of tinidazole against anaerobic bacteria and protozoa involves penetration of the drug into the cell of the micro-organism and subsequent damage of DNA strands or inhibition of their synthesis.

Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the synthesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units.

Related product monographs

Document Type Information Source  
 COLOBREATHE Inhalation powder, hard capsule MPI, EU: SmPC European Medicines Agency (EU)
 COLOMYCIN Powder for solution for injection / infusion / inhalation MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 COLY-MYCIN M Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 CUBICIN Powder for concentrate for solution for injection or infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FASIGYN Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FLAGYL Suppositories, Oral suspension MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)
 FOMICYT Powder for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FUCIDIN Oral Suspension MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 HIPREX Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 KIRIN Powder for suspension for injection MPI, EU: SmPC Υπουργείο Υγείας (CY)
 MACROBID Capsule MPI, US: SPL/Old FDA, National Drug Code (US)
 MACROBID Prolonged-release capsule MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MACRODANTIN Capsule MPI, US: SPL/Old FDA, National Drug Code (US)
 MONURIL Granules for oral solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MONUROL Granules for oral solution MPI, US: SPL/Old FDA, National Drug Code (US)
 ORBACTIV Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 PROMIXIN Powder for nebuliser solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SIVEXTRO Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 SIVEXTRO Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 TARGOCID Powder for solution for injection, infusion or oral solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TENKASI Powder for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 TRACTINFECT Powder for oral solution MPI, Generic Health Products Regulatory Authority (ZA)
 TRICHAZOLE Solution for infusion MPI, Generic Health Products Regulatory Authority (ZA)
 VIBATIV Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 XENLETA Concentrate and solvent for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 XENLETA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 XENLETA Solution for injection / Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 XYDALBA Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 ZYVOX Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 ZYVOXID Tablet / Solution for Infusion / Granules for suspension MPI, Generic Health Products Regulatory Authority (ZA)